美第奇新星生物技術 MNOV 深 滬
等待開盤 02-03 09:30:00 美东时间
1.66
-0.060
-3.49%
華盛通- 最 高1.75
- 今 開1.75
- 成交量 3.73万股
- 最 低 1.66
- 昨 收 1.72
- 總市值 8141.67万
- 52周最高 2.04
- 市盈率 靜 --
- 換手率 0.08%
- 52周最低 1.13
- 委 比 42.59%
- 總股本 4904.62万
- 歷史最高 14.50
- 量 比 0.48
- 振 幅 5.23%
- 歷史最低 1.12
- 每 手 1
- 風險率 0.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 苹果、SanDisk、西部数据、卡特彼勒、德克斯户外、霍尼韦尔、西南航空、万事达等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Praxis Precision Medicine"买入"评级，目标价从340美元升至1245美元；HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从10美元升至12美元
02-02 14:15
D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target
D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintains $9 price target.
01-30 20:50
MediciNova Reveals That As Of The End Of January 2026, 12 Sites In The US Are Activated And 100 Patients Have Been Enrolled In The SEANOBI Study
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that as of the end of January 2026,
01-30 07:03
MediciNova Reaches 100 Patients Enrolled in SEANOBI ALS Study for MN-166
MediciNova Reaches 100 Patients Enrolled in SEANOBI ALS Study for MN-166 MediciNova Inc. announced that 100 patients have been enrolled in the SEANOBI study, an Expanded-Access Program (EAP) evaluating MN-166 (ibudilast) in individuals with amyotrophic lateral sclerosis (ALS). The SEANOBI study, fun
01-30 07:00
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
MediciNova, Inc. announced that as of January 2026, 12 U.S. sites have activated and 100 patients with amyotrophic lateral sclerosis (ALS) have been enrolled in the SEANOBI study, representing 50% of the planned 200-enrollment. MN-166 (ibudilast) is being evaluated for ALS, with 100 patients enrolled under the NIH-funded SEANOBI Expanded Access Program. The program, supported by a $22 million NINDS grant, aims to provide MN-166 access to ALS pati...
01-29 23:00
2026 New Year’s Greetings from the CEO
MediciNova Inc., a biopharmaceutical company, reported significant progress in 2025 despite global challenges. Key achievements include completing patient enrollment in three clinical trials and launching an expanded access program for ALS with $22 million NIH funding. The COMBAT-ALS trial for ALS is in Phase 2b/3 and expects top-line results by year-end. The OXTOX study for chemotherapy-induced neuropathy and the MN-001 trial for hypertriglyceri...
01-06 14:00
MediciNova Establishes Flexible At-The-Market Equity Program
Medicinova ( ($MNOV) ) just unveiled an update. On December 29, 2025, MediciNov...
2025-12-30 21:20
MediciNova Completes Patient Enrollment in Mid-Stage Trial for Chemotherapy Nerve Damage
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful completion of patient
2025-12-18 19:08
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
2025-12-09 10:32
D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target
D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintains $9 price target.
2025-12-09 00:16
